At the outset, a range of breast cancer cell lines were incubated with FITC-labelled Herceptin, the relatively weak intensity of staining highlighted the inaccessibility of the Herceptin binding site on HER2 in contrast to the binding site for conventional anti- cerbB-2 antibodies (such as utilised in this study). The gene discussed is ERBB2; the disease is breast carcinoma.